Indivior Plc
INDV
Market Cap$2.89B
Close$
$-12.65
151.2% downside
Current Fair Value
151.2% downsideOvervalued by 151.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.89 Billion |
|---|---|
| Enterprise Value | $2.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.01 |
| Beta | 0.2 |
| Outstanding Shares | 134,848,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.31 |
|---|---|
| PEG | 8.82 |
| Price to Sales | 3.09 |
| Price to Book Ratio | -12.37 |
| Enterprise Value to Revenue | 2.11 |
| Enterprise Value to EBIT | 9.4 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.36 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...